Clinical Trial Update: Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase III study evaluating GTx-024 (enobosarm) for muscle wasting in patients with non-small cell lung cancer; results were posted in March 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GTx-024

Snippet

Sponsor: GTx | Conditions: Muscle Wasting, Non Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-03-03